Demirli Atici S, Canda AE, Terzi MC. Are current scales adequate for assessing quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? World J Clin Cases 2025; 13(22): 105884 [DOI: 10.12998/wjcc.v13.i22.105884]
Corresponding Author of This Article
Semra Demirli Atici, MD, Department of General Surgery, Acibadem Kent Hospital, 8229/1. Sk. No. 56, Izmir 35620, Türkiye. smrdemirli@hotmail.com
Research Domain of This Article
Surgery
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Are current scales adequate for assessing quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Semra Demirli Atici, Aras Emre Canda, Mustafa Cem Terzi
Semra Demirli Atici, Aras Emre Canda, Mustafa Cem Terzi, Department of General Surgery, Acibadem Kent Hospital, Izmir 35620, Türkiye
Semra Demirli Atici, Aras Emre Canda, Mustafa Cem Terzi, KRC Clinic for Colorectal Surgery and Peritoneal Surface Malignancies, Izmir 35220, Türkiye
Author contributions: Demirli Atici S, Canda AE and Terzi MC wrote the manuscript; Canda AE and Terzi MC reviewed and supervised the manuscript preparation; All authors read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All author(s) declare having no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Semra Demirli Atici, MD, Department of General Surgery, Acibadem Kent Hospital, 8229/1. Sk. No. 56, Izmir 35620, Türkiye. smrdemirli@hotmail.com
Received: February 10, 2025 Revised: April 5, 2025 Accepted: April 21, 2025 Published online: August 6, 2025 Processing time: 94 Days and 12.1 Hours
Abstract
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are complex surgical procedures that are often used to treat advanced cancers of the abdominal cavity with peritoneal metastasis. Although these treatments can be lifesaving, patients often experience a significant decrease in their overall quality of life (QoL), especially in the early stages of recovery, owing to the physical burden of surgery and the effects of chemotherapy. Many traditional QoL questionnaires have been used to measure CRS and HIPEC. However, these classical current QoL assessment tools often fail to capture the unique challenges faced by this population, including bowel dysfunction, stoma-related distress, and long-term survivorship issues. Therefore, additional parameters that assess bowel function and stoma opening status and especially patient-reported outcome measures would be useful in QoL measurements to provide a more detailed understanding of recovery and general well-being in these patients.
Core Tip: It is important to evaluate and improve the preoperative and postoperative quality of life (QoL) in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Owing to the physical burden of surgery and the effects of chemotherapy, patients experience a significant decrease in their QoL, especially in the early stages of recovery. We believe that it would be more appropriate to evaluate QoL in a study conducted in a heterogeneous patient group, including patient-reported outcome measures with parameters that also evaluate bowel function and stoma-opening status.
